[October 2, 2013 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses tomments issued on September 26, 2013 (the Staffs Letter) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the F-3) of Chinard Bloodrporation (thempany).]
[October 2, 2013 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses tomments issued on September 26, 2013 (the Staffs Letter) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the F-3) of Chinard Bloodrporation (thempany).]
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1) Amount (2) Proposed (1)(3) Proposed Amount of (4) Ordinary shares, par value $0.0001 per share Preferred shares, par value $0.0001 per share] [12 September 2013 Matter No.: Doc Ref: RJH/3780935 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com China Cord Blood Corporation th 48 1 Garden Road, Central Hong Kong S.A.R. Dear Sirs, Re: China Cord Blood Corporation (the “Company”) Registration Statement Commission Securities Act Ordinary Shares Preferred Shares Equity Securities Debt Securities (the “ Rights Units Securities We have acted as special] [345 Park Avenue New York, NY 10154-1895 Direct Main Fax September 12, 2013 China Cord Blood Corporation th 48 Re: Registration Statement on Form F-3 Ladies and Gentlemen: China Cord Blood Corporation September 12, 2013 2 Page China Cord Blood Corporation September 12, 2013 3 Page China Cord Blood Corporation September 12, 2013 4 Page The opinions set forth above] [. Year Ended March 31, 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 3.2 27.6 30.6 19.2 30.1 Earnings: Year Ended March 31, RMB000 2013 2012 2011 2010 2009 Income before income tax 158,185 151,599 132,142 79,663 42,299 Add: Fixed charges Interest expense 70,097] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation We consent to the use of our reports dated July 31, 2013, with respect to the consolidated balance sheets of China Cord Blood Corporation and subsidiaries as of March 31, 2012 and 2013, and the related consolidated statements of comprehensive income, changes in equity, and] [China Cord Blood Corporation 48th Floor , Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Madams and Sirs , We hereby consent to the use of our name under the captions "Enforceability of Civil Liabilities ", " Legal Matters " and " Experts " in the registration statement on Form F-3 (the " Registration Statement " r]
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1) Amount (2) Proposed (1)(3) Proposed Amount of (4) Ordinary shares, par value $0.0001 per share Preferred shares, par value $0.0001 per share] [12 September 2013 Matter No.: Doc Ref: RJH/3780935 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com China Cord Blood Corporation th 48 1 Garden Road, Central Hong Kong S.A.R. Dear Sirs, Re: China Cord Blood Corporation (the “Company”) Registration Statement Commission Securities Act Ordinary Shares Preferred Shares Equity Securities Debt Securities (the “ Rights Units Securities We have acted as special] [345 Park Avenue New York, NY 10154-1895 Direct Main Fax September 12, 2013 China Cord Blood Corporation th 48 Re: Registration Statement on Form F-3 Ladies and Gentlemen: China Cord Blood Corporation September 12, 2013 2 Page China Cord Blood Corporation September 12, 2013 3 Page China Cord Blood Corporation September 12, 2013 4 Page The opinions set forth above] [. Year Ended March 31, 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 3.2 27.6 30.6 19.2 30.1 Earnings: Year Ended March 31, RMB000 2013 2012 2011 2010 2009 Income before income tax 158,185 151,599 132,142 79,663 42,299 Add: Fixed charges Interest expense 70,097] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation We consent to the use of our reports dated July 31, 2013, with respect to the consolidated balance sheets of China Cord Blood Corporation and subsidiaries as of March 31, 2012 and 2013, and the related consolidated statements of comprehensive income, changes in equity, and] [China Cord Blood Corporation 48th Floor , Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Madams and Sirs , We hereby consent to the use of our name under the captions "Enforceability of Civil Liabilities ", " Legal Matters " and " Experts " in the registration statement on Form F-3 (the " Registration Statement " r]
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1) Amount (2) Proposed (1)(3) Proposed Amount of (4) Ordinary shares, par value $0.0001 per share Preferred shares, par value $0.0001 per share (5) Subscription rights Debt securities (6) Units Total unsold securities 68,500,000.00 4,884.05 (7) Total new securities] [12 September 2013 Matter No.: Doc Ref: RJH/3780935 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com Chinard Bloodrporation th 48 1 Garden Road, Central Hong KongR. Dear Sirs, Re: Chinard Bloodrporation (thempany) Registration Statementmmission Securities Act Ordinary Shares Preferred Shares Equity Securities Debt Securities (the] [345 Park Avenue New York, NY 10154-1895 Direct Main Fax September 12, 2013 Chinard Bloodrporation th 48 Re: Registration Statement on Form F-3 Ladies and Gentlemen: Chinard Bloodrporation September 12, 2013 2 Page Chinard Bloodrporation September 12, 2013 3 Page Chinard Bloodrporation September 12, 2013] [. Year Ended March 31, 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 3.2 27.6 30.6 19.2 30.1 Earnings: Year Ended March 31, RMB000 2013 2012 2011 2010 2009ome beforeome tax 158,185 151,599 132,142 79,663 42,299d: Fixed charges Interest expense 70,097 3,287 2,606 2,431 (1)] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation Wensent to the use of our reportsted July 31, 2013, with respect to thensolidated balance sheets of Chinard Bloodrporation and subsidiaries of March 31, 2012 and 2013, and the relatednsolidated statements ofmprehensiveome, changes in equity, andsh flows for each of the years] [Chinard Bloodrporation 48th Floor , Bank of China Tower 1 Garden Road Central Hong KongR. Madams and Sirs , We herebynsent to the use of our name under theptions "Enforceability of Civil Liabilities ", " Legal Matters " and " Experts " in the registration statement on Form F-3 (the]
[CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1) Amount (2) Proposed (1)(3) Proposed Amount of (4) Ordinary shares, par value $0.0001 per share Preferred shares, par value $0.0001 per share (5) Subscription rights Debt securities (6) Units Total unsold securities 68,500,000.00 4,884.05 (7) Total new securities] [12 September 2013 Matter No.: Doc Ref: RJH/3780935 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com Chinard Bloodrporation th 48 1 Garden Road, Central Hong KongR. Dear Sirs, Re: Chinard Bloodrporation (thempany) Registration Statementmmission Securities Act Ordinary Shares Preferred Shares Equity Securities Debt Securities (the] [345 Park Avenue New York, NY 10154-1895 Direct Main Fax September 12, 2013 Chinard Bloodrporation th 48 Re: Registration Statement on Form F-3 Ladies and Gentlemen: Chinard Bloodrporation September 12, 2013 2 Page Chinard Bloodrporation September 12, 2013 3 Page Chinard Bloodrporation September 12, 2013] [. Year Ended March 31, 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 3.2 27.6 30.6 19.2 30.1 Earnings: Year Ended March 31, RMB000 2013 2012 2011 2010 2009ome beforeome tax 158,185 151,599 132,142 79,663 42,299d: Fixed charges Interest expense 70,097 3,287 2,606 2,431 (1)] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation Wensent to the use of our reportsted July 31, 2013, with respect to thensolidated balance sheets of Chinard Bloodrporation and subsidiaries of March 31, 2012 and 2013, and the relatednsolidated statements ofmprehensiveome, changes in equity, andsh flows for each of the years] [Chinard Bloodrporation 48th Floor , Bank of China Tower 1 Garden Road Central Hong KongR. Madams and Sirs , We herebynsent to the use of our name under theptions "Enforceability of Civil Liabilities ", " Legal Matters " and " Experts " in the registration statement on Form F-3 (the]
[China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014 1Q14 Added 15,260 New Subscribers 1Q14 Revenue Up 11.6% YOY to RMB128.7 Million 1Q14 Operating Income Up 3.3% YOY to RMB45.9 Million Conference Call to be Held August 27, 2013 at 8:00 a.m. ET HONG KONG, China, August 26, 2013 -- China Cord Blood Corporation (NYSE:]
[Chinard Bloodrporation Reports Financial Results for the First Quarter of Fiscal 2014 1Q14ded 15,260 New Subscribers 1Q14 Revenue Up 11.6% YOY to RMB128.7 Million 1Q14 Operatingome Up 3.3% YOY to RMB45.9 Millionnferencell to be Held August 27, 2013 at 8:00 a.m. ET HONG KONG, China, August 26, 2013 -- Chinard Bloodrporation (NYSE:) (CCBC or thempany),]
[Chinard Bloodrporation Reports Financial Results for the First Quarter of Fiscal 2014 1Q14ded 15,260 New Subscribers 1Q14 Revenue Up 11.6% YOY to RMB128.7 Million 1Q14 Operatingome Up 3.3% YOY to RMB45.9 Millionnferencell to be Held August 27, 2013 at 8:00 a.m. ET HONG KONG, China, August 26, 2013 -- Chinard Bloodrporation (NYSE:) (CCBC or thempany),]
[TABLE OF CONTENTS PART I 4 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 4 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 4 ITEM 3. KEY INFORMATION 4 A. Selected financial data 4 B. Capitalization and Indebtedness 6 C. Reasons for the Offer and Use of Proceeds 7 D. Risk factors 7 ITEM 4. INFORMATION ON THE COMPANY 36] [Guangzhou City Real Estate Property Purchase Agreement Seller (Party A): Guangzhou Hezhong CD Manufacturing Co., Ltd. Legal Representative: ZHU Suifeng Buyer (Party B): Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. Legal Representative: ZHENG Ting Article I Party A desires to transfer the real estate property it owns, including the land use right to the surrounding public green area and road] [Hundsun (Hangzhou) Science & Technology Park Property Transfer Agreement Contract #: H216 ( Party A (Transferor): Hangzhou Hundsun Baichuan Technology Co., Ltd. Legal Representative: HU Weiguo Party B (Transferee): Beijing Jiachenhong Biological Technologies Co., Ltd. Legal Representative: DENG Yue Article I Background of the Construction Project Party A entered into an agreement “State Construction Land Use Right Transfer Contract” (contract] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 31, 2013 Ting Zheng Chief Executive Officer July 31, 2013 Albert Chen Chief Financial Officer (Principal Financial and Accounting Officer)] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors China Cord Blood Corporation: Hong Kong, China July 31, 2013]
